The results demonstrated that, compared with the CTBP1-AS2 group, restraining TGF-β1/SMAD2/3 pathway reduced CRC cell proliferation (Figures 4B,C), enhanced the cell apoptosis (Figure 4D), and inhibited the CRC cell invasion (Figure 4E). Here, SMAD2 is linked to colorectal carcinoma.